This research was developed by MacLean DB and Luo LG, at the Division of Endocrinology, Hallett Center for Diabetes and Endocrinology, Brown Medical School, Providence.
Briefing of the report:
A steroidal glycoside with anorectic activity in animals, termed P57AS3 (P57), was isolated from Hoodia gordonii and found to have homologies to the steroidal core of cardiac glycosides. Intracerebroventricular (i.c.v.) injections of the purified P57AS3 demonstrated that the compound has a likely central (CNS) mechanism of action.
There is no evidence of P57AS3 binding to or altering activity of known receptors or proteins, including Na/K-ATPase, the putative target of cardiac glycosides. The studies demonstrated that the compound increases the content of ATP by 50-150% in hypothalamic neurons.
In addition, third ventricle (i.c.v.) administration of P57, which reduces subsequent 24-h food intake by 40-60%, also increases ATP content in hypothalamic slice punches removed at 24 h following the i.c.v. injections.
In related studies, in pair fed rats fed a low calorie diet for 4 days, the content of ATP in the hypothalami of control i.c.v. injected animals fell by 30-50%, which was blocked by i.c.v. injections of P57AS3. With growing evidence of metabolic or nutrient-sensing by the hypothalamus, ATP may be a common currency of energy sensing, which in turn may trigger the appropriate neural, endocrine and appetitive responses as similar to other fundamental hypothalamic homeostatic centers for temperature and osmolarity.
Despite the similarities (including the appetite-suppressing effect) between P57 and cardiac glycosides, however, initial studies with P57 failed to show any effect on Na/K-ATPase receptors, indicating that P57 is probably not a cardiac glycoside. P57 also failed to show an effect on a wide range of other types of receptors. Thus its mode of action at the cellular level was somewhat of a mystery.
Compiled from EntrezPubMed